We will have to wait for FULL AD data - not TLD, and see if blows away even a hint of doubt about statistical and clinical significance, before even making an argument for either AA or BTD. ( Post BIIB fiasco, FDA will not be taking chances - at least that is my take).
I do not want to guess when that data will be available.
Market Data 
Markets 
AI
